Denis Corin has spent the last 13 years in the biopharmaceutical industry watching and learning from scientists and companies that fail.
“I’ve seen so many promising and innovative young technologies really struggle along or die on the vine because they’re run by scientists who don’t really understanding capital raising,” he told Drug Delivery Business News. “They run out of ‘friends and family money’ and they get stuck in this limbo land of trying to raise the next round of capital to get their product to the next step in its product development evolution.”
As chairman and CEO of Q Biomed (OTC:QBIO), Corin tries to solve this problem for scientists with interesting ideas – if they bring the technology, he’ll bring the capital.
Get the full story at our sister site, Drug Delivery Business News.
The post Q Biomed looks to dust off shelved cancer pain drug appeared first on MassDevice.